Scisparc Stock Price, News & Analysis

SciSparc (Nasdaq: SPRC), a clinical-stage pharmaceutical company, reported significant progress in its proposed reverse merger with AutoMax Motors, Israel's exclusive importer of JAC electric vehicles. The SEC has declared effective the Form F-4 registration statement for the merger on July 21, 2025.

The merger agreement, initially announced in April 2024, will result in SciSparc acquiring 100% of AutoMax's share capital. Special shareholder meetings are scheduled for August 25, 2025 (SciSparc) and August 28, 2025 (AutoMax) to vote on the merger approval. The transaction remains subject to shareholder approvals from both companies and Israeli court approval.

SciSparc Ltd. (Nasdaq: SPRC) and Clearmind Medicine have filed an international patent application for a novel combination therapy using MEAI and PEA compounds, targeting obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).

The therapy combines 5-methoxy-2-aminoindane with N-Acylethanolamines (MEAI) and Palmitoylethanolamide (PEA) to address global health challenges affecting over 890 million people with obesity and 30% of the global adult population with non-alcoholic fatty liver disease (NAFLD). This development expands their existing patent portfolio across multiple jurisdictions.

SciSparc Ltd. (Nasdaq: SPRC), a clinical-stage pharmaceutical company focused on central nervous system disorders and rare diseases, has successfully regained compliance with Nasdaq's minimum bid price requirement. The company received official notification from Nasdaq on July 18, 2025, confirming that its shares maintained a closing bid price of $1.00 or higher for 10 consecutive business days, satisfying Listing Rule 5550(a)(2).

With this achievement, Nasdaq has closed the previous bid price deficiency matter, marking an important milestone for SciSparc's continued listing on the exchange.

SciSparc (Nasdaq: SPRC), a clinical-stage pharmaceutical company focused on central nervous system disorders, has announced a 1-for-21 reverse share split effective July 3, 2025. The company's outstanding shares will be reduced from 11,225,751 to approximately 534,600 shares, with about 516,727 shares publicly held.

The stock will continue trading under the symbol "SPRC" on the Nasdaq Capital Market with a new CUSIP number M82618121. The reverse split, approved by shareholders in October 2024, will not alter shareholders' ownership percentages except for minor adjustments due to fractional share treatment. All outstanding options and warrants will be proportionally adjusted.

SciSparc Ltd. (SPRC) has announced the publication of a Japanese divisional patent application for a novel pharmaceutical combination. The patent covers an innovative combination of paracetamol and palmitoylethanolamide (PEA) designed to enhance pain and fever relief while requiring lower doses than traditional paracetamol treatments.

The combination aims to provide a safer and more effective treatment option by leveraging PEA's ability to boost the body's endocannabinoid system. This synergistic approach could potentially reduce the risk of liver damage associated with paracetamol while improving therapeutic outcomes for acute, chronic, and neuropathic pain, as well as fever management.

SciSparc Ltd. (SPRC) and Clearmind Medicine Inc. (CMND) announced the publication of a European patent application for their combination therapy targeting cocaine addiction. The treatment combines Clearmind's MEAI (5-methoxy-2-aminoindane) with SciSparc's Palmitoylethanolamide.

The patent is based on preclinical trials conducted at Bar-Ilan University's Gonda Multidisciplinary Brain Research Center. The research demonstrated that MEAI significantly reduced cocaine-seeking behavior in animals without affecting their natural reward responses, suggesting its specificity in targeting drug-related compulsions. This European patent application adds to existing applications filed in the U.S. and other global territories.

SciSparc (Nasdaq: SPRC) and Clearmind Medicine have filed an international patent application for a novel treatment targeting eating disorders, including anorexia and bulimia. The treatment combines 3-Methylmethcathinone (3-MMC) with SciSparc's Palmitoylethanolamide (PEA).

The collaboration aims to address the complex neurobiological and psychological aspects of eating disorders, which are among the top ten leading causes of disability in young women. Recent statistics show that eating disorders affect up to 70 million people globally, with prevalence rates increasing from 3.4% to 7.8% between 2000 and 2018, particularly among children and adolescents.

SciSparc (Nasdaq: SPRC) and Clearmind Medicine have achieved a significant milestone with the publication of their patent application in South Korea for a novel cocaine addiction treatment. The therapy combines Clearmind's MEAI (5-methoxy-2-aminoindane) with SciSparc's PEA (Palmitoylethanolamide).

The patent application is supported by promising preclinical trial results from Bar-Ilan University's Gonda Multidisciplinary Brain Research Center. The research demonstrated that MEAI significantly reduced cocaine-induced craving in animal subjects without affecting their natural reward responses, such as sucrose seeking behavior. This suggests the treatment specifically targets drug-related compulsions while preserving normal reward mechanisms.

This South Korean patent application adds to the companies' existing intellectual property portfolio, which includes multiple applications filed in the United States and other global territories.

SciSparc (Nasdaq: SPRC) has signed a definitive agreement to sell its entire 52.73% ownership stake in MitoCareX Bio , a cancer therapeutics drug discovery company, to N2OFF Inc. (Nasdaq: NITO). The transaction includes:

- $700,000 cash payment for 4,961 MitoCareX shares
- Exchange of remaining shares for 40% of N2OFF's fully diluted capital stock
- Potential additional N2OFF stock up to 25% based on milestones
- 30% share of N2OFF's financing proceeds over 5 years (max $1.6M)
- N2OFF's commitment to invest $1M in MitoCareX post-closing

The deal requires N2OFF shareholder approval and must close within 30 days. Dr. Alon Silberman will continue as CEO with a 5% restricted stock grant vesting over 3 years. Upon completion, MitoCareX will become a wholly-owned subsidiary of N2OFF.